Mounjaro Injections: What You Actually Need to Know Before You Start

Your first pen: what the 2.5 mg starting dose is actually doing

Picture this. The pen arrives, you've read the leaflet twice, and the needle looks more intimidating than it is. The 2.5 mg dose you're starting on isn't there to produce dramatic results, its job is to let your body adjust to tirzepatide without the GI system staging a full protest. Most people tolerate the first four weeks reasonably well; the nausea that gets mentioned tends to land harder at the step-up doses.

What tirzepatide is doing from day one is activating two separate gut-hormone pathways. GIP and GLP-1 receptors both play roles in appetite signalling and blood-sugar regulation; hitting both simultaneously is what makes tirzepatide's mechanism distinct from single-receptor medicines. You probably won't feel a sharp reduction in appetite in week one. The effect builds gradually, which is partly why the titration schedule exists. For a fuller explanation of the receptor science, the page on how Mounjaro injections work goes deeper into the pharmacology.

One practical habit worth building from injection one: before you use a new pen, check the solution through the window, it should be clear and colourless. If it looks cloudy or has particles, don't use it. Takes about ten seconds, and it matters.

Injecting correctly, sites, technique and needle changes

The injection itself is subcutaneous, meaning it goes into the fatty tissue just below the skin rather than into muscle. The three approved sites are the abdomen (avoiding the two inches around the navel), the outer thigh, and the upper arm. Rotating between them each week isn't optional hygiene, it meaningfully reduces the chance of lipodystrophy, where repeated injections into the same spot change the tissue underneath and can affect how the medicine absorbs.

Technique is straightforward once you've done it once. Pinch the skin if you're lean, press the pen firmly against the site, press the button and hold for about ten seconds until the window turns yellow. The needle is short (4 mm or 8 mm depending on the pen format) and most people find the sting unremarkable. A step-by-step walkthrough of each stage is covered in the Mounjaro injection technique guide, including what the click and yellow indicator actually mean.

One thing that catches people out: the needle should be changed with every injection, not reused. Reused needles blunt quickly, which makes the injection sharper and increases infection risk. The 100-pack of compatible needles is available from our pharmacy if you need a resupply between prescriptions. Dispose of used needles in a registered sharps container, pharmacies and GP surgeries offer collection.

Side effects you're likely to encounter and a few you should take seriously

The side-effect profile of Mounjaro injections is led almost entirely by the gastrointestinal system. Nausea is the most reported complaint, followed by loose stools or constipation (sometimes both at different points), reflux, burping and a general fatigue around dose-change weeks. For most people these aren't severe, they're uncomfortable and often front-loaded into the first week at a new dose, then settle. Eating smaller meals, reducing fat content temporarily and staying well-hydrated all help.

There's one symptom cluster that warrants urgent medical attention rather than watchful waiting. The MHRA issued a formal Drug Safety Update in January 2026 flagging acute pancreatitis as an infrequent but serious risk with GLP-1 class medicines: severe stomach pain that doesn't pass and may radiate through to the back, with or without vomiting, is a reason to stop injecting and seek same-day medical help. This isn't a reason to avoid treatment, it is a reason to know the symptom. You can report any suspected reactions through the MHRA's Yellow Card scheme.

Storage matters too. Mounjaro pens are kept refrigerated at 2–8°C. If a pen has been left out, the question of whether it's still usable depends on how long and at what temperature, the guide on what to do if your Mounjaro was left out of the fridge covers the SmPC-referenced windows. When in doubt, contact our clinical team rather than guessing.

What the clinical evidence says about injections Mounjaro produces results from

In the SURMOUNT-1 trial (2,539 adults with obesity, no diabetes, 72 weeks) participants on the 15 mg dose achieved an average body-weight reduction of around 20–21%, with some analyses reaching higher. That figure is cited by NICE in their December 2024 appraisal of tirzepatide (TA1026), which recommends Mounjaro for adults with a BMI of 35 or above and at least one weight-related condition on the NHS pathway. Private eligibility thresholds are lower, per the licensed indication: BMI 30 or above, or 27 with a qualifying condition.

Those numbers come from clinical trial conditions, structured diet support, regular follow-up, consistent dose titration. Real-world outcomes vary. What doesn't vary is that the Mounjaro injection itself has to be done consistently and correctly to produce anything close to those results. The full overview of the Mounjaro programme (including how the pen design works and how many injections each pen contains) is covered on the Mounjaro treatment page. If you're comparing this treatment against others or thinking about private costs, the UK price comparison page sets out what private treatment typically costs and what should be included.

If you'd like a prescriber to assess whether Mounjaro injections are appropriate for you, check your eligibility with a free consultation, reviewed the same day by a GPhC-registered prescriber, never by an algorithm.